Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul;84(7):857-862.
doi: 10.1007/s40265-024-02058-9. Epub 2024 Jun 21.

Sotatercept: First Approval

Connie Kang  1
Affiliations
Review

Sotatercept: First Approval

Connie Kang. Drugs. 2024 Jul.

Abstract

Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that is being developed by Merck and Co., Inc. (Rahway, NJ, USA) for the treatment of pulmonary arterial hypertension. Sotatercept recently received approval in the USA for the treatment of adults with pulmonary arterial hypertension [World Health Organisation (WHO) Group 1] to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events. This article summarizes the milestones in the development of sotatercept leading to this first approval for pulmonary arterial hypertension.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Merck Sharp & Dohme LLC. WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf . Accessed 21 May 2024.
    1. Nabeh OA, Saud AI, Amin B, et al. A systematic review of novel therapies of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2024;24(1):39–54. - DOI - PubMed
    1. Merck Sharp & Dohme. FDA approves Merck's WINREVAIR(Tm) (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO* Group 1) [media release]. 26 Mar 2024. http://www.merck.com .
    1. Merck. Our pipeline at a glance. 2024. https://www.merck.com/research/product-pipeline/ . Accessed 21 May 2024.
    1. Celgene Corporation. Acceleron Pharma announces global collaboration with Celgene Corporation on ACE-011 program for cancer-related bone loss [media release]. 21 Feb 2008. http://www.celgene.com .

MeSH terms

LinkOut - more resources